Cadrenal Therapeutics, Inc. (CVKD)
Nasdaq: CVKD · Pharmaceutical Preparations · Ponte Vedra, FL · filing with the SEC since 2022
Who owns Cadrenal Therapeutics, Inc.
As filed with the SECHolders of 5% or more
2
Quang X. Pham holds 23.6% of Common Stock, $0.001 par value per share, as its SCHEDULE 13D filed Jan 29, 2025 says.
Directors and officers
6
report now, of 10 people on the record since 2023. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 2 named at left.
Holders of 5% or moreshare of the class, as filed
Quang X. Pham
SCHEDULE 13D · filed Jan 29, 2025 · Common Stock, $0.001 par value per share
PNC Financial Services Group
SCHEDULE 13G · filed Aug 7, 2026 · Common Stock
Havlickova 648 a.s.
SCHEDULE 13G/A · filed Feb 12, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%
John Raymond Murphy
SCHEDULE 13G/A · filed Jan 15, 2025 · Common Stock, $0.001 par value per share · reported falling below 5%
What CVKD reports owning in othersstakes of 5% or more, and other ties
Cadrenal Therapeutics, Inc. reports no stake in another company in the record.
Insider tradesForm 4
27sales
0purchases
24sales on a scheduled plan
2people selling
$500,000sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 13, 2025 to Oct 13, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 13, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window2 of 10 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Pham Quang X | Chairman and CEO | 25 | $400,000 | 22 | 0 | $0 |
| Szot Matthew K | Chief Financial Officer | 4 | $100,000 | 4 | 0 | $0 |